Using the right cell line might sound like a topic for Lab Work 101, but it is an issue at the heart of the reproducibility problem in preclinical research. A panel that met to discuss strategies for tackling the problem agreed that some emerging technologies for authenticating cell lines could make a difference, but found little common ground on which entities -journals, funding agencies or the private sector -should be responsible for mandating their use. The panel was convened by the Global Biological Standards Institute in November as part of its inaugural BioPolicy Summit and focused on cell line authentication -a key factor identified in the institute's 2013 white paper on the need for standards in many areas of preclinical research. GBSI President Len Freedman told BioCentury that although several issues were outlined in that analysis, the institute chose to start with this topic "because it is a clearly identifiable problem with known effects on results in research. " To include a cross-section of stakeholders in the discussion, GBSI drew the four panelists from Roche's Genentech Inc. unit, NIH's National Institute of General Medical Sciences (NIGMS), the Prostate Cancer Foundation (PCF) and Nature Publishing Group (NPG). Multiple studies have reported that up to one third of all cell lines used in preclinical research are misidentified -a problem that stems from lack of best handling practices and results in cross-contamination of cell lines. Cell line misidentification actually involves multiple issues, including whether a cell line was correctly identified before use, whether that line becomes contaminated or otherwise altered during experimentation, and whether multiple daughter cell lines generated from one cell line retain identity with one another and with their parent line. However, the panelists said despite growing awareness of the issue, many researchers still don't validate their cell lines. "Cell lines that were tagged as misidentified back in the 1960s are still used" under their wrong identity by some researchers, said panelist Véronique Kiermer, executive editor and director of author and reviewer services at NPG. "The consequences of using misidentified cells can be very different depending on the study being done. " JANUARY 15, 2015 COVER STORY
THE RIGHT CULTURE
Stakeholders agree that mandating new methods to authenticate cell lines can improve reproducibility in research, but they don't agree on who should lead the charge.
PRODUCT R&D 6 EPIZYME'S MANTLE PIECE
Epizyme adds PRMT5 to the list of epigenetic targets and believes it has a first-in-class inhibitor of the enzyme.
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A UT Austin team has engineered chimeric mAbs that induce more potent leukocyte-mediated killing of targeted cells than conventional IgGs.
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CONSORTIA CROSS-TALK
Consortia are wising up to the need to avoid duplication of efforts and starting to coordinate their activities, but still need to bring more academics into the fold.
Panelist Richard Neve, director of discovery oncology at Genentech, noted that although the implications for science already done would never be fully known, the emphasis now should be forward looking. "We need to set new standards to increase the integrity of the science we do from now on, " he told the panel. Jon Lorsch, director of NIGMS, said his institute recognizes the problem as a serious one and is implementing its own strategy for addressing it at the source of funding. "We're formulating new guidelines and procedures and asking grant applicants to have a statement about authenticating cell lines, " he said. Howard Soule, CSO of PCF, indicated the not-for-profit sector is taking action as well. "We take this issue very seriously as a responsibility to our donors, " he said. His organization is also tying it to funding, and about a year ago began requiring its researchers to show cell line authentication results within one year of receiving grant money.
STR-AIGHT TALK
All four panelists pointed to short tandem repeat (STR) analysis as the best available -if not the optimum -tool for authenticating cell lines. The approach involves profiling hypervariable regions in DNA that are unique to an individual genome, which provides a distinct genetic fingerprint for any human cell line. Many CROs and service companies now offer STR analysis to customers for about $150 per cell line with a turnaround time of about a week. But according to Kiermer, data collected by NPG from manuscript submissions show that only about 10% of researchers use STR analysis. She thinks that as its costs continue to decrease, the technique will become routine. In the meantime, Lorsch told BioCentury, the cost of STR analysis presents researchers with a significant barrier to compliance. "For example, if you have eight or nine people on your team working with a dozen cell lines and you're doing STR on all of them every few months, this adds up, " he said.
Neve told BioCentury that to use the technique "at the level you should" was too time-consuming and costly even for Genentech. "This is why we went with SNP-based profiling over STR, which could cost us tens of thousands of dollars annually. " In 2008, Genentech launched an in-house facility that banks all cell lines coming into the company and authenticates them before and after use by company researchers with a methodalso developed in-house -that utilizes 48 SNPs. "The initial cost of reagents is about $6 per sample for the SNP-based method and $15-$30 per sample for STR, depending on which kit you use, " Neve told Biocentury. "The SNP profiling also cuts the run-time by a factor of 4 or 5 over STR analysis. " "We've not looked at whether we see more reproducibility, but we do catch mistakes earlier, " Neve told the panel. "We can have more confidence moving forward that the data being produced will be reproducible. " Lorsch called Genentech's approach "a step in the right direction, " but was not convinced it would provide a comprehensive solution because not every researcher has the resources or motivation to set up an SNP-based authentication facility. "We want to make it more feasible for researchers to do cell line authentications in terms of the time, money and number of cell lines tested" -making it as easy as using a pH meter in a laband NIH is considering how to encourage development of new technologies in this area, he told the panel. Lorsch also told BioCentury that new technologies are needed because STR lacks the genomic resolution needed to authenticate gene-edited cell lines. "For instance, it can't tell you whether your HeLa cell line is the same as mine. So it would be useful to have a rapid, cost-effective technique that could do this. " Keith Yamamoto, keynote speaker at the GBSI summit, agreed that STR analysis is limited in its ability to identify cell lines, especially in light of gene-editing techniques that are becoming more common. "In my view it would be more useful to have a broader discussion on whether STR is really useful and how to develop new assays to identify cell lines, " he told BioCentury.
"We need to set new standards to increase the integrity of the science we do from now on."
Following those meetings, some journals began instituting measures to encourage researchers to adhere to best practices while others augmented their existing measures or hung back waiting for further developments, said Kiermer. NPG, for example, created an 18-point checklist for submitters that requests details about the study, including methods of statistical analysis, the source of cell lines used, and whether the cell lines and reagents used had been validated.
Kiermer told BioCentury that last June, to raise the baseline for the quality of data and to improve reporting across the board, "NIH initiated a workshop for journal editors, at which journals that had tried certain measures could discuss their experiences, the reactions they had received from authors and reviewers, and whether we could do more as a community."
The principal agreed-upon measures were for journals to issue statements about their policy on statistical analysis; require authors to fill out a checklist about sample collection methods, randomization and blinding; recommend that authors submit their data to public repositories, where available and ethically appropriate; and eliminate or reduce limits on the length of the methods section, in print and online.
Because not all journals have the same resources to devote to requesting and policing standards, the guidelines represent a core -not a comprehensivelist that representatives attending the workshop could commit to implementing, Kiermer told BioCentury.
According to the NIH's website, nearly 80 editors representing about 150 journals had signed on to the proposed guidelines by early January.
"We're not just expecting best practices," Kiermer said. "We're raising awareness around the issues of reproducibility as well. In turn, we hope this will affect people's thinking and behavior" and begin changing the culture of preclinical research.
-Michael J. Haas "I think cell lines will eventually have to be bar-coded. " Yamamoto is vice chancellor for research at the University of California, San Francisco, and executive vice dean at the UCSF School of Medicine.
POLICE QUESTION
There was less harmony among panelists on who should shoulder the responsibility for mandating standards or policing compliance. Kiermer's position was that journals can impose standards for publication that might provide an incentive for better behaviors, but journals cannot be responsible for ensuring that researchers act as they should. That requires other stakeholders, she said. "It's a community issue about good lab management and best practices -like asking a cook to use the freshest ingredients, " she told the panel. Monitoring compliance with standards also poses a significant administrative burden to journals, she said. "You have to police everything or it becomes a box-ticking exercise" that may have no actual impact on the quality of the data. "It's more complicated than accepting the researcher saying, 'I did it' , " she told BioCentury. "So you have to monitor that what you've asked for has been done, and evaluate the results of an STR analysis. At NPG journals, we have professional, inhouse editors whom we can ask to take on some of that burden. But it's difficult to scale the burden for academic journals whose editors might have day jobs. " Different stakeholders are starting to come together. Kiermer told the panel that NPG asks authors submitting manuscripts to complete an 18-point checklist that includes questions about the source of cell lines used and whether they have been authenticated. Additionally, in cooperation with NIH, NPG JANUARy 15, 2015 TOC
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and more than 100 other journals have developed and proposed a core set of guidelines for reporting preclinical research that they would ask all authors to follow (see "Journals take on reproducibility, " page 3). Lorsch said NIH could play a similar role by making proper cell authentication a condition of funding, but thought the cost of following up to ensure compliance would be far more than NIH could afford. "We are planning to ask grant applicants to make a statement about how they will validate cell lines and other reagents they use, and it would be a condition of the award, " he told BioCentury. "For example, if a grant recipient publishes a paper partway through the project and doesn't mention cell line validation, then we can address it by making compliance a condition of further funding or grant renewal. " "But we can't police ten thousand grants to make sure everyone is using STR on every single cell line, every single time, " in an NIH-funded project, he told the panel. Yamamoto also told BioCentury that NIH should take the lead in determining the relevance of each cell line and model to human biology and disease, "because it is difficult to motivate the private sector" to investigate this. But he also noted that regardless of how well authenticated a cell line is, it remains a limited system for evaluating compounds or representing human disease. "We expect a lung cell line to be more like a human lung than another organ, and we expect one cell to become two eventually, " he said. "But the biology is a lot more complex than that. We need to acknowledge that complexity. And we need to say to the public that no matter how carefully and tightly we control the variables, there is a whole iceberg of unknown variables underneath and we just have to live with that. Just saying this to public would be useful. " "There have been one or two PRMT5 inhibitors that have been presented from academic groups that are micromolar inhibitors and are not cell penetrant, " he told BioCentury. "This is the first example of a PRMT5 inhibitor that hits the target potently and selectively, gets into cells, has biological activity inside cells, and that biological activity translates into an anti-cancer activity in animal models. "
BLOCKING THE DRIVER
In biochemical studies, EPZ015666 blocked PRMT5 activity with K i ~5 nM and was highly selective, showing about 20,000-fold lower activity against all other HMTs tested.
"This is the first example of a PRMT5 inhibitor that hits the target potently and selectively, gets into cells, has biological activity inside cells, and that biological activity translates into an anti-cancer activity in animal models."
The compound inhibited proliferation of at least five MCL cell lines at low nanomolar concentrations and displayed strong anti-tumor activity in two mouse MCL xenograft models when administered orally. Suppression of tumor growth correlated quantitatively with inhibition of methylation on a marker protein inside the tumor, which supports the claim its effect in cancer is mediated via inhibition of the methyltransferase. Data were presented at the American Society of Hematology meeting in 2014.
Copeland told BioCentury he was optimistic about the PRT5 inhibitor's therapeutic index. "Over the course of that 21-day treatment regimen at all the doses we did not see any significant weight loss in the animals or any other sign of a safety issues, " he said.
Copeland added that EPZ015666 is a tool compound, not intended for the clinic, that has "attractive properties for the academic community to use as a probe. " He said Epizyme would make it available to the scientific community to further explore the biology and pathophysiology of PRMT5.
HISTONE METHYLTRANSFERASES AS DRIVERS OF CANCER
Dendograms of the methyltransferase families, indicating subsets with cancer-associated abnormalities (green spheres). These result either directly from up-regulation or alterations of methyltransferase genes or indirectly from up-regulation, mutations or alterations in pathways with which the methyltransferase interacts. There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a network of coordinated consortia, but bringing more academics into the fold could be critical for success. Consortia have emerged as a specialized form of publicprivate partnership that join multiple partners from academic, industry, regulatory and other government or non-government organizations to achieve common goals. The model has gained traction in the last decade as stakeholders have looked for ways to make academics' work more directly relevant to the requirements for developing drugs, and bring fresh thinking to pharmas that want access to cutting edge science. Over the past three years, at least 20 new consortia have been formed worldwide to promote drug development (see "Consortia composition, " page 14). However, as the number of consortia has grown, partners have started to ask themselves how they can measure results and ensure the model advances productivity. "We focused in the past about how to get collaboration within a consortium or within a collaborative effort, but the time has come that we really have to think about how we collaborate across these consortia to make sure we're leveraging the limited resources we all have and we can more quickly advance to the objectives we want to achieve, " said Martha Brumfield at a meeting last month of the EU's Innovative Medicines Initiative (IMI) and the Critical Path Institute (C-Path).
Brumfield is president and CEO of C-Path. The advantage of consortia, she said, is that "by joining forces, we speed up the process, prevent duplication of efforts, decrease the number of animals used and save time and resources along the way. The goal of the meeting was to discuss ways of improving the productivity of consortia and strategies for promoting coordination across consortia working towards similar goals.
In particular, the organizations explored lessons learned from the collaboration launched in 2013 between C-Path's PSTC consortium and IMI's SAFE-T consortium, both of which were designed to identify biomarkers for drug-induced organ injuries.
SAFETY IN NUMBERS
PSTC was launched in 2006 to bring big pharma and regulatory agencies together to identify biomarkers that could give clues about potential drug toxicity in preclinical studies. But in 2009, IMI launched the SAFE-T consortium with about 75% overlapping membership to PSTC and an overlapping scope. SAFE-T was set up to concentrate specifically on the kidneys, liver and vasculature -and was designed to identify clinical biomarkers for toxicity affecting those organs. "Because the two consortia had their own separate identitiestheir own frameworks -we recognized that we needed to have some type of legal framework, " said Denise Robinson-Gravatt, formerly senior director and head of science and technology in drug safety R&D at Pfizer. She serves on the advisory committee for PSTC and on the steering committee for SAFE-T.
The six-year SAFE-T consortium is officially coming to an end this June, and both C-Path and IMI consider the collaboration between SAFE-T and PSTC a success. According to Robinson-Gravatt, there were several discrete factors behind that success. Those included a mutual "Now that we're getting data from many of these collaborative efforts we can learn what is working well."
Martha Brumfield, C-Path understanding of how the consortia were different, shared objectives, a common vision, open information sharing and transparency, joint work plans to address regulatory feedback, and identification of ways in which one consortium could fill the gaps of the other. Michel Goldman, executive director of IMI, added that the involvement of both U.S. and European regulatory agencies was also critical to the partnership's success. "By having C-Path and IMI collaborating, this encourages the FDA and EMA to collaborate even further as well, " he told BioCentury. "This cooperation increases the probability that both agencies will make similar decisions. " Brumfield told BioCentury that the ability of the two consortia to put their respective funds towards the same objectives was also a key factor for success. "When different groups are working on a similar topic, they are limited to whatever funding they can access, " she said. "Having the ability to tap into different funding sources when working together brings more resources for the shared objectives. " She added: "Funds have not been exchanged between IMI and C-Path. However, work load and work product are shared, as appropriate. " But despite the positives, the two consortia have been slow to generate measurable results for industry members. To date, they have not produced a qualified safety biomarker that companies can use in clinical trials as an accepted indicator of safety by regulatory agencies. John-Michael Sauer, a toxicologist at C-Path and executive director of PSTC, said at the meeting that the problem is that the criteria for qualified biomarkers are not yet defined. He added that determining the criteria for a qualified biomarker is an iterative process that benefits from close cooperation between the regulatory agencies and other stakeholders. Frank Sistare, executive director of safety assessment at Merck, added that regulatory agencies will need to incorporate the findings and recommendations from the consortia into regulatory practice if industry players are going to remain involved. "When we talk about metrics of success, if a publication is worth maybe a dime, a regulatory decision that says these biomarkers are now useful for these purposes is worth like a million dollars, " he said at the meeting. "You could have a million publications out there that could be ignored. " Ameeta Parekh, R&D director at FDA's Office of Women's Health, added: "I think declaring those small wins and declaring them often, and really identifying them early takes you a long way. Getting a regulatory endorsement on something really is very meaningful. But he said it's much harder to get academics to participate because there's little incentive for them, given the current reward system in universities that places a priority on publications rather than translational output. Chin added that to bring academics to the table, their participation will have to have some payoff for their careers. "In most institutions, the world between basic science and clinical work is a Never Never Land, " he said. "In some instances, it is still considered as pejorative. There needs to be recognition of the importance of this bridging activity. " He added: "In academia, you don't promote a team -you promote an individual. We still do not have a very good way of being able to recognize an individual's contribution on a team. " In addition, as ever, much of the issue for academics comes down to money. Janet Woodcock, director of FDA's Center for Drug Evaluation and Research (CDER), said the academic community needs two things: money and recognition. "There currently is not a reliable stream of funding for these types of activities in the U.S. and the recognition is very lame. It doesn't have the same cachet as the laboratory research. " "It unfortunately all does come back to money, " David Wholley, director of the Biomarkers Consortium said at the meeting. He added that NIH is making progress on providing incentives for academic researchers to do team science, work on joint publications and make data widely available and reliable. "I think really that's the only way to move things forward, " he said, "because unless people see that as a condition of grant award, they're going to behave the way their institutions are incenting them and the institutions are still incenting them around the old system of recognition and reward. " Part of the solution is keeping in mind each consortium member's stake and motivation for remaining involved. Dalvir Gill told the meeting that consortia "fail more often than they succeed. When you have multiple stakeholders, often they pull in different directions. If you have a problem to fix, you are kind of pulling at the problem. The more efficient you become, somebody somewhere is losing something if you have multiple stakeholders pulling that problem apart. " Gill is CEO of TransCelerate BioPharma Inc. He attributes the not-for-profit's success to its single stakeholder group: pharmaceutical companies.
Meanwhile, C-Path and IMI are continuing to work together. They have organized a partnership with a memorandum of understanding between C-Path's CPTR (Critical Path to TB Drug Regimens) and IMI's PreDiCT-TB (Preclinical development of anti-tuberculosis drug combinations) consortia to develop tuberculosis treatments. CPTR is evaluating in vitro models and clinical trial designs, PreDiCT-TB is developing animal models. The two PPPs are also informally collaborating on Alzheimer's disease (AD) research programs. "In my personal opinion, collaboration is critical to fulfill our mission at IMI, " Goldman said. "We need to not only continue this collaboration with C-Path, but also to expand the collaboration further. I am stepping down soon and am personally quite strong on collaboration, but I don't doubt that IMI will continue to work in these cooperative models in the future. "
"In most institutions, the world between basic science and clinical work is a Never Never Land. In some instances, it is still considered as pejorative. There needs to be recognition of the importance of this bridging activity." The ability to analyze RNA, DNA and protein from single cells will allow researchers to see things that they would not otherwise see. If you look at the bulk average of a population of cells it is a lie and you just get the wrong answer. " The deal, announced in mid-December, formalizes an existing collaboration between Fluidigm and the founders of the Single Cell Genomics Centre (SCGC) on the Wellcome Trust Genome Campus. The informal phase of the partnership started in 2013 prior to the researchers forming SCGC. According to Jones, the alliance started when Fluidigm determined that microfluidics could help enable single cell analysis. The partners' first project was studying RNA at a single cell level. Jones said one of the early tests of Fluidigm's system for single-cell preparation and mRNA sequencing was in John Marioni's lab at EMBL-EBI. Using Fluidigm's single cell RNA analyzer, Marioni's team demonstrated differences in transcriptional activity between cells in apparently homogeneous cultures. The researchers analyzed mRNA levels from a few hundred single cells from the same culture and found greater heterogeneity in transcript levels than in the cell population as a whole. Fluidigm now has launched a single cell DNA sequencing project. "We see that as an opportunity that is as big as RNA, " Jones said. "Now we have the ability to look at the whole exome, targeted regions of the genome, or even the whole genome, and there is interest also in the Sanger Institute for that. " He added that scientists at SCGC are most interested in cell lineage and the possibility that tracking mutations from cell to cell could allow a cell lineage tree to be constructed. Although this technique has been used on worms, he said, it hasn't been used on humans and this technology may soon make that possible. "It would be fascinating to understand the entire cell lineage tree of the human organism, " he said. Nadeau's work focuses on oral immunotherapy for food allergies, which involves retraining the immune system by eating very small doses of food allergens.
In her earlier studies, Nadeau combined the approach with anti-IgE therapy. Now she wants to go a step further and understand its molecular basis. "Our goal, " she told BioCentury, "is to look for the cause and the cure for allergies in general. " One avenue she is already pursuing is the design of nanoparticles to encase food proteins. To do so, she will look for external collaborators like Stephen Miller, professor of microbiology-immunology at Northwestern University Feinberg School of Medicine. "The nanoparticles Dr. Miller has developed are actually made with a natural substance and are already being used in people, " Nadeau said. "So we're hoping to get a relatively quick FDA approval. " The Center also will house clinical trials and has lined up two Phase I studies for its first year. But Nadeau said a key to the center's long-term success will be moving beyond the clinic and training physicians to implement treatments developed there. Plans were in place "even before Sean had come on board, " she said, to train staff from centers across the country to perform trials, and Nadeau now plans to host visiting scholars from around the world and link satellite centers for further collaboration. 
INDICATION: Autoimmune
In vitro and mouse studies suggest DUBA-expressing T cells could help treat autoimmune diseases. In mice with conditional T cell deletion of DUBA, interleukin-17 (IL-17) production was higher in T helper type 17 (Th17) cells than in Th17 cells from mice with normal DUBA expression. In mouse models of anti-CD3 antibody-induced inflammation, DUBA deficiency in T cells increased Th17 cell infiltration into the small intestine and increased inflammation compared with normal DUBA expression. Next steps could include identifying a method for treating inflammation by modulating DUBA expression. 
THERAPEUTICS INDICATION: Brain cancer
Mouse and cell culture studies suggest ANG4043, a conjugate of the brainpenetrant peptide angiopep-2 and an anti-HER2 mAb, could help treat brain cancer. In mice with HER2-positive brain tumors, IV infusion of ANG4043 resulted in accumulation of the conjugate in the brain and increased survival compared with an unconjugated anti-HER2 mAb or vehicle. Next steps could include testing ANG4043 additional rodent brain tumor models and assessing its safety profile.
Angiochem Inc. has ANG4043 in preclinical development for cancer. NanoFlares could be used to detect CTCs from whole blood samples. NanoFlares are gold nanoparticles linked to single-stranded DNA complementary to mRNA targets and a fluorescent reporter that is activated upon target binding. In whole blood spiked with human breast cancer cells, NanoFlares designed to recognize the cancer-associated genes vimentin (VIM) or fibronectin 1 (FN1; FN) detected live cancer cells at concentrations as low as 100 cells per 1 mL blood. Co-incubation of blood samples from a mouse model of metastatic breast cancer with the VIMand FN1-targeted NanoFlares produced a fluorescent signal whereas a scrambled control probe did not. Next steps could include using NanoFlares to detect CTCs in patient blood samples. 
ASSAYS AND SCREENS TECHNOLOGY: SNPs
Genetic sequencing studies identified rare mutations in LDLR and APOA5 that could predict risk of early onset MI. Exome sequencing of 9,793 early onset MI patients in different cohorts identified rare non-synonymous mutations associated with a 4.2-fold increased risk of MI and null alleles associated with 13-fold increased risk compared with controls without the mutations. Exome sequencing also identified rare non-synonymous mutations in APOA5 associated with 2.2-fold higher MI risk. Patients with LDLR mutations had elevated LDL cholesterol while patients with APOA5 mutations had elevated triglyceride levels compared with patients and controls without the mutations. Next steps could include validating the biomarkers in addiitonal cohorts. 
DRUG DELIVERY TECHNOLOGY: Polymers
In vitro and sheep studies suggest 3D printed polymeric scaffolds could help regenerate meniscus tissues. In vitro, a polymeric human meniscus scaffold that sequentially exposed human synovial mesenchymal stem cells to recombinant human connective growth tissue factor (CTGF) and then recombinant human transforming growth factor (TGF) β1 (TGFB1) induced their differentiation into fibrocartilaginous-like cells and stimulated formation of a fibrocartilaginous matrix. In a sheep model of meniscus injury, an implanted 3D printed scaffold that enables controlled release of the two growth factors integrated with existing tissue, produced a native meniscus cartilage pattern and had improved mechanical properties compared with a scaffold without the growth factors. Next steps include a clinical trial to evaulate the polymeric scaffold. 
TECHNOLOGY: Polymers
Mouse studies suggest new self-adjuvanting polymers could help deliver tumor peptides to the immune system to boost antitumor immune response to a vaccine. Tumor vaccines were synthesized by conjugating a tumor peptide derived from human papillomavirus HPV-16 E7 oncoprotein with several alkyne-functionalized poly(t-butyl acrylate) polymers. In a mouse model of E7-positive tumors, vaccination with the conjugated tumor vaccine resulted in decreased tumor volume and increased survival compared with delivery of unconjugated tumor peptide mixed with an adjuvant. Next steps include extending the studies to additional tumor models and testing the vaccine in combination with other anticancer agents. 
